Talk:Brilaroxazine

good to add history
"Reviva’s lead drug candidate, brilaroxazine (RP5063), is a multimodal modulator of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors and D2, D3, D4 dopamine receptors in clinical development for multiple neuropsychiatric indications including schizophrenia, bipolar disorder, major depressive disorder (MDD), psychotic and agitation symptoms in dementia or Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD). Beyond its use in CNS disorders, brilaroxazine has also been granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for development in two respiratory indications in which serotonin signaling plays a central role in triggering pathology—pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF)."

https://www.nature.com/articles/d43747-021-00068-0

https://esmed.org/MRA/mra/article/view/3837

https://www.jneurology.com/articles/brilaroxazine-rp5063-clinical-experience-in-schizophrenia--a-new-option-to-address-unmet-needs.html

Lazzldkdm (talk) 08:55, 28 June 2024 (UTC)